ID Pharma to supply vector for clinical trial of gene therapy for retinitis pigmentosa

The physician-led clinical trial will start 2017 at Kyushu University under Kohei SONODA on incorporating human pigment epithelium-derived factor within a therapeutic vector to human patients. 5 years of animal experiments on this procedure did indicate no problems.

Nikkei Biotech news release, July 22, 2016

Most popular posts: